We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Springworks Therapeutics Inc
5 watching
Current Price
$31.4
$1.5
(5.02%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,958.82M
52-Week High
65.92
52-Week Low
13.6
Average Volume
0.5M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,958.82M52-Week High65.9252-Week Low13.6Average Volume0.5MDividend Yield--P/E Ratio--What does the Springworks Therapeutics Inc do?
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations, which is in Phase I clinical trial. The company has collaborations with BeiGene, Ltd., GlaxoSmithKline LLC, and Allogene to develop combination approaches with nirogacestat and mirdametinib; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. In addition, the company has clinical collaboration agreement with Janssen Biotech, Inc., Precision BioSciences, Inc., Seagen Inc., and AbbVie, Inc. SpringWorks Therapeutics, Inc. was founded in 2017 and is headquartered in Stamford, Connecticut.
Read More
How much money does Springworks Therapeutics Inc make?
News & Events about Springworks Therapeutics Inc.
Globe Newswire
1month ago
STAMFORD, Conn., Dec. 27, 2022 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, announced today that the Company has completed the submission ...
PR Newswire
3 months ago
Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma Applied BioMath, LLC Announces Collaboration with SpringWorks Therapeutics, Inc. for Systems Pharmacology Modeling in Multiple Myeloma PR Newswire CONCORD, Mass...
Ticker Report
3 months ago
Cwm LLC lowered its stake in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX Get Rating) by 12.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 37,968 shares of the companys...
PR Newswire
3 months ago
Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028 Central Nervous System Disorders Therapeutics Market Expected to Reach $159 Billion by 2028 PR Newswire Palm Beach, Fla., Oct. 12, 2022 FinancialNewsMedia.com News Commentary Palm Beach, Fla., Oct. 12, 2022...
Frequently Asked Questions
Frequently Asked Questions
What is Springworks Therapeutics Inc share price today?
Can Indians buy Springworks Therapeutics Inc shares?
How can I buy Springworks Therapeutics Inc shares from India?
Can Fractional shares of Springworks Therapeutics Inc be purchased?
What are the documents required to start investing in Springworks Therapeutics Inc stocks?
What is today’s traded volume of Springworks Therapeutics Inc?
What is today’s market capitalisation of Springworks Therapeutics Inc?
What is the 52-Week High and Low Range of Springworks Therapeutics Inc?
What percentage is Springworks Therapeutics Inc down from its 52-Week High?
What percentage is Springworks Therapeutics Inc up from its 52-Week Low?
Current Price
$31.4
$1.5
(5.02%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.